Markets

Taking a Look at the Operational Data for Merck & Co., Inc. (MRK)

Merck & Co., Inc. (NYSE:MRK) is an interesting stock at present. Now trading with a market value of 180.47B, the company has a mix of catalysts and obstacles that spring from the nature of its operations. Everyone seems to have their own opinion of this stock. But what do the numbers really say? We think it’s a great time to take a fresh look.

Merck & Co., Inc. (NYSE:MRK) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For MRK, the company currently has 7.79 billion of cash on the books, which is offset by 3.18 billion in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 92.8 billion in total assets, balanced by 53.09 billion in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

Merck & Co., Inc. (MRK) saw 2.92 billion in free cash flow last quarter, representing a quarterly net change in cash of -3.92 billion. Perhaps most importantly where cash movements are concerned, the company saw about 3.32 billion in net operating cash flow.



Merck & Co., Inc. (NYSE:MRK) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 9.88 billion in total revenues. That represents a quarterly year/year change in revenues of 0.01 in sequential terms, the MRK saw sales decline by 0.06.

But what about the bottom line? After all, that’s what really matters in the end. Merck & Co., Inc. (MRK) is intriguing when broken down to its core data. The cost of selling goods last quarter was 3 billion, yielding a gross basic income of 6.88 billion. For shareholders, given the total diluted outstanding shares of 2.75 billion, this means overall earnings per share of 0.71. Note, this compares with a consensus analyst forecast of 1.03 in earnings per share for its next fiscal quarterly report.




Is Merck & Co., Inc. (NYSE:MRK) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 4.17 in total earnings per share. If we consider a median price to earnings ratio on the stock, that corresponds with a stock price of 15.47. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on Merck & Co., Inc..

Previous ArticleNext Article

Related Post

It’s worth it to have a look at Extended Sta... Extended Stay America, Inc. (NYSE:STAY) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value o...
Looking at the Big Picture for NewLink Genetics Co... NewLink Genetics Corporation (NASDAQ:NLNK) is one the of the active stocks and its unusual movement is rasing eyebrows among traders. Now trading with...
Why You Should Want To Trade Sirius XM Holdings In... Sirius XM Holdings Inc. (NASDAQ:SIRI) is one of the more popular stocks investors are adding into their watchlist. Now trading with a market value of ...
Pfizer Inc. (PFE) vs. Impax Laboratories, Inc. (IP... Pfizer Inc. (NYSE:PFE) and Impax Laboratories, Inc. (NASDAQ:IPXL) are the two most active stocks in the Drug Manufacturers - Major industry based on t...
Dissecting the Numbers for MicroVision, Inc. (MVIS... MicroVision, Inc. (NASDAQ:MVIS) and Dolby Laboratories, Inc. (NYSE:DLB) are the two most active stocks in the Diversified Electronics industry based o...